Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
Anumana Appoints Harry S. Palmin as CFO
Anumana Appoints Harry S. Palmin as CFOCAMBRIDGE, Mass. – May 14, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…May 14, 2024
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…December 05, 2025
Anumana Named to Fast Company’s 2024 Next Big Things in Tech Awards
Award recognizes Anumana’s innovative AI-driven cardiovascular disease detection technologyNovember 19, 2024